Antidepressant options: Venlafaxine in perspective

Journal of Clinical Psychopharmacology

Volumn 16, Issue 3 SUPPL. 2, 1996, Pages

  Thase, Michael E ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; NORADRENALIN; SEROTONIN; VENLAFAXINE;

DEPRESSION; HUMAN; PRIORITY JOURNAL; REVIEW;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRAIN; CYCLOHEXANOLS; DEPRESSIVE DISORDER; HUMANS; NOREPINEPHRINE; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0030014201     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199606002-00003     Document Type: Article

References (18)

1. Thase ME, Howland R. Biological processes in depression: an updated review and integration. In: Beckham E, Leber EE, eds. Handbook of depression. 2nd ed. New York: Guilford Publications, 1995:213-79.
2. Delgado PL, Price LH, Heninger GR, Charney DS. Neurochemistry. In: Paykel ES, ed. Handbook of affective disorders. 2nd ed. New York: Guilford Publications, 1992;219-53.
3. Asberg M, Bertilsson L, Martensson B, Scalia-Tomba G-P, Thoren P, Traskman-Bendz L. CSF monoamine metabolites in melancholia. Acta Psychiatr Scand 1984;69:201-19.
4. Davis JM, Koslow SH, Gibbons RD, Maas JW, Bowden CL, Casper R, Hanin I, Javaid JI, Chang SS, Stokes PE. Cerebrospinal fluid and urinary biogenic amines in depressed patients and healthy controls. Arch Gen Psychiatry 1988;45:705-17.
5. Gibbons RD, Davis JM. Consistent evidence for a biological subtype of depression characterized by low CSF monoamine levels. Acta Psychiatr Scand 1986;74:8-12.
6. Roy A, Pickar D, Linnoila M, Potter WZ. Plasma norepinephrine level in affective disorders. Relationship to melancholia. Arch Gen Psychiatry 1985;42:1181-5.
7. Depue RA, Spoont MR. Conceptualizing a serotonin trait. A behavioral dimension of constraint. Ann N Y Acad Sci 1989;487:47-62.
8. Carroll BJ. Psychopathology and neurobiology of manic-depressive disorders. In: Carroll BJ, Barrett JE, eds. Psychopathology and the brain. New York: Raven Press, 1991:265-85.
9. Gold PW, Goodwin FK, Chrousos GP. Clinical and biochemical manifestations of depression: relation to the neurobiology of stress. Parts 1 and 2. N Engl J Med 1988;319(6):348-53,
10. Gold PW, Goodwin FK, Chrousos GP. N Engl J Med 319(7):413-20.
11. Nemeroff CB. New vistas in neuropeptide research in neuropsychiatry: focus on corticotropin-releasing factor. Neuropsychopharmacology 1992;6:69-75.
12. Willner P. Animal models as simulations of depression. Trends Pharmacol Sci 1991;12:131-6.
13. Weiss JM. Stress-induced depression: critical neurochemical and electrophysiological changes. In: Madden J, ed. Neurobiology of learning, emotion, and affect. New York: Raven Press, 1991:123-54.
14. Baxter LR, Schwartz JM, Phelps ME, Mazziotta JC, Guze BH, Selin CE, Gerner RH, Sumida RM. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry 1989;46:243-50.
15. Berman KF, Doran AR, Pickar D, Weinberger DR. Is the mechanism of prefrontal hypofunction in depression the same as in schizophrenia? Regional cerebral blood flow during cognitive activation. Br J Psychiatry 1993;162:183-92.
16. Kupfer DJ. Sleep research in depressive illness: clinical implications - a tasting menu. Biol Psychiatry 1995;38:391-403.
17. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992;149:999-1010.
18. Depression Guideline Panel. Clinical practice guideline number 5. Depression in primary care: Vol. 2. Treatment of major depression. AHCPR Publication No. 93-0551. Rockville, MD: US Dept. of Health and Human Services, Agency for Health Care Policy and Research, 1993.